Search

Displaying results 41 - 50 of 6090 in total
  1. Drug

    Trastuzumab

    go.drugbank.com/drugs/DB00072
    ApprovedInvestigational

    While Ogivri is the first biosimilar approved in the U.S. for the treatment of breast cancer or stomach cancer, it is the second biosimilar approved in the U.S. for the treatment of cancer. … Herzuma (trastuzumab-pkrb) is a biosimilar drug approved in December 2018 for the treatment of HER2-overexpressing breast cancer.

    Mixtures: PHESGO Solution for Subcutaneous Injection 600mg/600mg/10mL, PHESGO Solution for Subcutaneous Injection 1200mg/600mg/15mLProducts: TRAZIMERA (POWDER FOR CONCENTRATE FOR SOLUTION FOR INFUSION 150 MG/VIAL), TRAZIMERA (POWDER FOR CONCENTRATE FOR SOLUTION FOR INFUSION 440 MG/VIAL)
  2. Drug

    Iloprost

    go.drugbank.com/drugs/DB01088
    ApprovedInvestigational

    Iloprost is an analog of prostacyclin (PGI2; epoprostenol), an endogenous prostanoid mainly produced in the vascular endothelium. It is more stable than prostacyclin, which is short-lived. Iloprost consists of a mixture of the 4R and 4S ...

    Products: Iloprost Zentiva 10 Mikrogramm/ml Lösung für einen Vernebler, Iloprost Zentiva 20 Mikrogramm/ml Lösung für einen Vernebler
  3. Drug

    Mycophenolate mofetil

    go.drugbank.com/drugs/DB00688
    ApprovedInvestigational

    [L7363] It is marketed by Roche Pharmaceuticals and was granted FDA approval for the prophylaxis of transplant rejection in 1995. … [A180826] In addition to the above uses, mycophenolate mofetil has also been studied for the treatment of nephritis and other complications of autoimmune diseases.

    Products: Mycophenolatmofetil Accord 500 mg Pulver für ein Konzentrat zur Herstellung einer Infusionslösung, CELLCEPT FOR I.V. INFUSION 500 mg/vial
  4. Drug

    Dornase alfa

    go.drugbank.com/drugs/DB00003
    ApprovedInvestigational

    Dornase alfa is a biosynthetic form of human deoxyribunuclease I (DNase I) enzyme. It is produced in genetically modified Chinese hamster ovary (CHO) cells using recombinant DNA technology. The 260-amino acid sequence of dornase alfa is ...

    Products: ./2,5 ml - Lösung für einen Vernebler
  5. Drug

    Ceftazidime

    go.drugbank.com/drugs/DB00438
    ApprovedInvestigational

    Bacteria possess a cell wall comprising a glycopeptide polymer commonly known as peptidoglycan, which is synthesized and remodelled through the action of a family of enzymes known as "penicillin-binding proteins" (PBPs). β-lactam antibio...

    Mixtures: Zavicefta (Ceftazidime 2g/Avibactam 0.5g) Powder for Concentrate for Solution for Infusion, CEFAZIME FOR INJECTION 1 g/vialCategories: Antibacterials for Systemic Use, Antiinfectives for Systemic Use
  6. Drug

    Bevacizumab

    go.drugbank.com/drugs/DB00112
    ApprovedInvestigational

    vials formulated for intravenous oncology use. … There is a great deal of evidence indicating that vascular endothelial growth factor (VEGF) is important for the survival and proliferation of cancer cells.

    Categories: Experimental Unapproved Treatments for COVID-19Products: ZIRABEV CONCENTRATE FOR SOLUTION FOR INFUSION 100 MG/4 ML, ZIRABEV CONCENTRATE FOR SOLUTION FOR INFUSION 400 MG/16 ML
  7. Drug

    Antihemophilic factor human

    go.drugbank.com/drugs/DB13192
    ApprovedInvestigational

    Antihemophilic factor human is approved by the Food and Drug Administration for use in hemophilia A (classical hemophilia) for the prevention and control of hemorrhagic episodes [FDA Label]. … Exogenous replacement of Factor VIII is currently the cornerstone of Hemophilia treatment and is used for the prophylaxis and control of bleeding episodes.

    Mixtures: Haemate P Powder and solvent for solution for injection or infusion, Haemate P 1000IU Powder and solvent for solution for injection or infusionProducts: NUWIQ POWDER AND SOLVENT FOR SOLUTION FOR INJECTION 500 IU, NUWIQ POWDER AND SOLVENT FOR SOLUTION FOR INJECTION 250 IU
  8. Drug

    Aflibercept

    go.drugbank.com/drugs/DB08885
    ApprovedInvestigational

    [L47966,L47971] The intravitreal formulation, under the brand name EYELEA, was approved by the FDA for the treatment of retinopathy of prematurity in preterm infants in February 2023 and for the treatment … [L47976] An aflibercept biosimilar, Yesafili, was approved for use in the EU in September 2023.

    Products: ZALTRAP CONCENTRATE FOR SOLUTION FOR INFUSION 25 MG/ML, Zaltrap 25mg/ml Concentrate for Solution for Infusion
  9. Drug

    Coagulation Factor IX (Recombinant)

    go.drugbank.com/drugs/DB00100
    Approved

    Recombinant Factor IX is indicated for the control and prevention of bleeding episodes in adult and pediatric patients with congenital factor IX deficiency (Hemophilia B). … Factor IX complex), and is instead produced by a genetically engineered Chinese hamster ovary (CHO) cell line that secretes recombinant Factor IX into cell medium that is then processed and purified for

    Products: BeneFIX Powder and Solvent for Solution for Injection 250iu/vial, BeneFIX Powder and Solvent for Solution for Injection 1000iu/vial
  10. Drug

    Enoxaparin

    go.drugbank.com/drugs/DB01225
    ApprovedInvestigational

    Enoxaparin is a common low-molecular-weight heparin (LMWH) used in the prevention and management of various thromboembolic disorders. Initially approved by the FDA in 1993, it is administered by a subcutaneous or intravenous injection an...

    Products: ./0.6ML FER, ./0.8ML FER